Le Lézard
Classified in: Health, Science and technology, Business
Subjects: EARNINGS, Conference Call, Webcast, Advisory

TFF Pharmaceuticals to Hold Fourth Quarter and Full-Year 2019 Financial and Business Results Conference Call on March 26, 2020


TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that it will release its financial results for fourth quarter and full-year 2019 and business update on Thursday, March 26, 2020. The Company's management will host a conference call to discuss the financial results and provide a business update on recent corporate and clinical developments at 8:30 a.m. Eastern Time.

Conference Call Details:

Thursday, March 26, 2020, 8:30 a.m. Eastern Time (ET)

Domestic Dial-In Number: Toll-Free: (800) 816-3024

International Dial-In Number (857) 770-0106

Conference ID: 7695599

Webcast URL: https://edge.media-server.com/mmc/p/k9qym597

The conference call will also be broadcast live and available for replay for one month on the Company's website, https://tffpharma.com, in the Events Calendar of the Investors section. Please access the Company's website at least 15 minutes ahead of the conference to register, download, and install any necessary audio software.

About TFF Pharmaceuticals' Thin Film Freezing technology platform

TFF Pharmaceuticals' Thin Film Freezing (TFF) platform was designed to improve the solubility and absorption of poorly water-soluble drugs and is particularly suited to generate dry powder particles with properties targeted for inhalation delivery, especially to the deep lung, an area of extreme interest in respiratory medicine. The TFF process results in a "Brittle Matrix Particle," which possesses low bulk density, high surface area, and typically an amorphous morphology, allowing the particles to supersaturate when contacting the target site, such as lung tissue. Based upon laboratory experiments, the aerodynamic properties of the particles are such that the portion of a drug deposited to the deep lung has the potential to reach as high as 75 percent.

About TFF Pharmaceuticals

TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing, or TFF, technology platform. Early testing confirms that the TFF platform can significantly improve the solubility and absorption of poorly water-soluble drugs, a class of drugs that comprises approximately one-third of the major pharmaceuticals worldwide, thereby improving their pharmacokinetics. TFF Pharmaceuticals has two lead drug candidates: Voriconazole Inhalation Powder and Tacrolimus Inhalation Powder. The Company plans to add to this pipeline by collaborating with large pharmaceutical partners. The TFF Platform is protected by 39 patents issued or pending in the US and internationally. To learn more about TFF Pharmaceuticals and its product candidates, visit the Company's website at https://tffpharma.com.

###


These press releases may also interest you

at 09:03
Today Vertafore announced the expansion of its open agency management system architecture with the addition of five new members to the Vertafore Orange Partner Program and the release of AMS360 Connecttm.  ...

at 09:00
The cryptocurrency market continues to remain volatile in 2020, attracting an increasing number of people. With more retail investment funds pouring into the industry, the need for state-of-the-art crypto exchange services became a crucial need....

at 09:00
iiRcade, Inc., the ultimate connected arcade machine that allows gamers of all ages to own and play their favorite retro and modern arcade games at home, is pleased to announce that classic games by Psikyo are coming exclusively to the home arcade...

at 09:00
Service Objects, the leading provider of real-time global contact validation solutions, is currently offering government agencies and public health authorities at all levels access to its services to assist in their contact tracing initiatives. These...

at 09:00
The ongoing coronavirus pandemic will have long-term consequences for the federal budget, including the Social Security program's finances. While the annual Social Security Trustees Report released April 22, 2020 did not account for the effects of...

at 09:00
Forcura, a healthcare technology company that enables safer patient care transitions along the care continuum, announces that it plans to create 115 jobs in Jacksonville by the end of 2022. The company will receive taxpayer-backed incentives from the...



News published on 19 march 2020 at 09:05 and distributed by: